BioSpace News Archive

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Board.

Genome Medical, a leader in telegenomics-based clinical care, today announced that it has expanded its services to enable collaborative population genomics programs with health systems across the country.

Incyte announced that it has scheduled its fourth quarter and year-end 2019 financial results conference call and webcast for 8:00 a.m. ET on Thursday, February 13, 2020.

Agilent Technologies Inc. (NYSE: A) today announced that Mark Doak, Agilent senior vice president and president of the Agilent CrossLab Group, has decided to retire on May 1, 2020.

PathoQuest, a company with expertise in genomic analysis, announced today that it has received GLP certificate of conformity following a successful inspection by the French National Agency for Medicine and Health Products Safety (ANSM).

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has regained the rights to rigosertib in Greater China.

Noblegen Inc. (“Noblegen”), is excited to announce that they have been selected as part of the Canadian Government’s delegation invited to the 2020 Cleantech Forum in San Francisco January 27-29, 2020.

Medtronic plc (NYSE:MDT) today announced the launch of Efficio™, a cloud-based data management software for use with the SynchroMed™ II intrathecal drug delivery system, that will allow clinicians to more efficiently manage their targeted drug delivery pump practices to treat patients with chronic pain, cancer pain and severe spasticity.

Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced the pricing of an underwritten public offering of 1,625,000 shares of its common stock at a price to the public of $18.50 per share.

Trust Transparency Center (TTC) is pleased to announce the formation of the Ingredient Transparency Center (ITC).